SMTL ID : 5jm5.1

Crystal structure of AKR1C3 complexed with a pro-drug

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.99 Å

Oligo State

homo-dimer

Ligands

2 x NAP: NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)

NAP.1: 29 residues within 4Å: Chain A: G.22, T.23, Y.24, D.50, Y.55, K.84, H.117, S.166, N.167, Q.190, Y.216, S.217, A.218, L.219, G.220, S.221, Q.222, L.236, A.253, L.268, A.269, K.270, S.271, Y.272, N.273, R.276, Q.279, N.280 Ligands: 6LG.2 26 PLIP interactions: 26 interactions with chain A Hydrogen bonds: A:T.23, A:Y.24, A:D.50, A:S.166, A:N.167, A:N.167, A:S.217, A:L.219, A:S.221, A:Q.222, A:Q.222, A:Q.222, A:K.270, A:S.271, A:Y.272, A:N.280, A:N.280 Water bridges: A:S.217, A:A.218, A:T.251, A:R.276, A:R.276 Salt bridges: A:K.270, A:R.276 pi-Stacking: A:Y.216 pi-Cation interactions: A:R.276 NAP.4: 29 residues within 4Å: Chain B: G.22, T.23, Y.24, D.50, Y.55, K.84, H.117, S.166, N.167, Q.190, Y.216, S.217, A.218, L.219, G.220, S.221, Q.222, L.236, A.253, L.268, A.269, K.270, S.271, Y.272, N.273, R.276, Q.279, N.280 Ligands: 6LG.5 27 PLIP interactions: 27 interactions with chain B Hydrogen bonds: B:T.23, B:Y.24, B:D.50, B:S.166, B:N.167, B:Q.190, B:S.217, B:L.219, B:S.221, B:Q.222, B:Q.222, B:Q.222, B:K.270, B:S.271, B:Y.272, B:N.280, B:N.280 Water bridges: B:S.217, B:A.218, B:S.221, B:T.251, B:R.276, B:Q.279 Salt bridges: B:K.270, B:R.276 pi-Stacking: B:Y.216 pi-Cation interactions: B:R.276

3 x 6LG: (1R)-1-{3-[3-(dimethylcarbamoyl)phenoxy]-4-nitrophenyl}ethyl bis[(aziridin-1-yl)]phosphinate(Non-covalent)

6LG.2: 16 residues within 4Å: Chain A: Y.24, L.54, Y.55, W.86, H.117, S.118, P.119, M.120, S.129, N.167, Y.216, W.227, F.306, F.311, P.318 Ligands: NAP.1 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:W.86, A:W.86 pi-Stacking: A:W.227 pi-Cation interactions: A:W.227 6LG.5: 17 residues within 4Å: Chain B: Y.24, L.54, Y.55, W.86, H.117, S.118, M.120, S.129, N.167, Y.216, R.226, W.227, F.306, F.311, P.318, Y.319 Ligands: NAP.4 4 PLIP interactions: 4 interactions with chain B Hydrophobic interactions: B:W.86, B:W.86 pi-Stacking: B:W.227 pi-Cation interactions: B:W.227 6LG.6: 11 residues within 4Å: Chain B: Q.6, C.7, V.8, V.18, R.258, L.261, Q.262, G.264, V.265, V.266, F.284 4 PLIP interactions: 4 interactions with chain B Hydrophobic interactions: B:V.8, B:V.18, B:L.261, B:Q.262

1 x 6NY: 3-{2-(hydroxyamino)-5-[(1S)-1-hydroxyethyl]phenoxy}-N,N-dimethylbenzamide(Non-covalent)

6NY.3: 10 residues within 4Å: Chain A: Q.6, C.7, V.8, V.18, R.258, L.261, Q.262, G.264, V.265, F.284 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:V.8, A:V.18, A:L.261 Hydrogen bonds: A:Q.6, A:R.258

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

He, P. et al., An AKR1C3 based Pro-drug TH3424 has potent anti-tumor activity against liver cancer. To Be Published

Release Date

2017-05-03

Peptides

Aldo-keto reductase family 1 member C3: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Aldo-keto reductase family 1 member C3